Category: 3. Business

  • Assessing Valuation After Recent Momentum in Share Performance

    Assessing Valuation After Recent Momentum in Share Performance

    MSCI (MSCI) recently caught investors’ attention after its performance over the past month saw shares rise by nearly 3%. With steady annual revenue and net income growth, many are watching to see whether this momentum will continue.

    See our latest analysis for MSCI.

    Momentum around MSCI has been building again, as reflected by its 6.6% share price return over the past 90 days. While its share price is down slightly year-to-date, the company has still delivered a healthy 17% total shareholder return over the last three years. This reminds investors that steady growth can pay off over the long run.

    If you’re interested in other opportunities with solid growth and active management, now is a great time to broaden your search and discover fast growing stocks with high insider ownership

    But after strong returns and solid earnings growth, the real question is whether MSCI’s current price leaves upside on the table or if the market has already factored in all the company’s future potential.

    MSCI’s most-followed narrative sets its fair value significantly above the last closing price, highlighting a notable disconnect between market sentiment and analyst models. This contrast draws extra attention to what’s driving that upside, and serves as a springboard for deeper analysis.

    Substantial growth in asset-based fee revenue is being driven by surging global flows into ETFs and index-linked products, especially for non-U.S. and international exposures, underscoring persistent structural demand for MSCI’s indices as capital allocators seek globally diversified portfolios, which directly boosts revenue and earnings.

    Read the complete narrative.

    Want to know the secret behind that ambitious target? The narrative is powered by bold projections about expanding margins and buybacks, but which forecasts truly move the needle? Find out what estimates have investors so bullish, and see the projections the Street is betting on.

    Result: Fair Value of $655.06 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, a slowdown in Sustainability products and intensifying competition could limit MSCI’s growth potential and challenge the bullish outlook that is currently priced in.

    Find out about the key risks to this MSCI narrative.

    Looking at MSCI through the market’s lens, the company trades at a price-to-earnings ratio of 35.8x, which is notably higher than its industry peers (24.4x) and the fair ratio of 16.6x. That premium signals high confidence in future growth, but also raises the stakes. Could expectations be running ahead of reality?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:MSCI PE Ratio as at Nov 2025

    If you want to dig in for yourself or have a different take on MSCI’s prospects, dive into the data and craft your own perspective in just a few minutes. Do it your way.

    A great starting point for your MSCI research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    Don’t let your next smart move pass you by. The market is teeming with high-potential stocks, and now is your chance to get ahead of the curve.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include MSCI.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • How Investors May Respond To MarketAxess (MKTX) Launching Standardized U.S. Credit Auctions and Dividend Announcement

    How Investors May Respond To MarketAxess (MKTX) Launching Standardized U.S. Credit Auctions and Dividend Announcement

    • MarketAxess Holdings announced the launch of the first standardized market-wide auction protocol for U.S. credit trading and reported third-quarter revenue of US$208.82 million, alongside a quarterly cash dividend of US$0.76 per share payable December 3, 2025.

    • The company’s new auction trading platform and continued dividend payments highlight its focus on product innovation and returning capital to shareholders amid sustained trading volume growth in key portfolios.

    • We’ll explore how the introduction of standardized auction protocols for U.S. credit trading influences MarketAxess’s investment narrative and growth outlook.

    AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

    MarketAxess appeals to investors who believe in the growth of electronic fixed-income trading and the company’s potential to broaden its leadership beyond U.S. high-grade bonds. The recent launch of a standardized U.S. credit auction protocol may help address concerns around core market share by encouraging more electronic block trading, but it does not materially alter the near-term catalyst or the ongoing risk of competition from established and emerging platforms. Among recent developments, the introduction of Opening and Closing Auctions stands out, as it directly targets improvements in price discovery and liquidity, key factors for driving electronic adoption and offsetting margin pressures from lower-fee protocols. However, investors should be mindful that despite new product rollouts, intensifying competition continues to pressure fees and market share, which…

    Read the full narrative on MarketAxess Holdings (it’s free!)

    MarketAxess Holdings’ outlook forecasts $1.1 billion in revenue and $370.5 million in earnings by 2028. This is based on a 7.9% annual revenue growth rate and represents a $147.7 million increase in earnings from the current $222.8 million.

    Uncover how MarketAxess Holdings’ forecasts yield a $202.67 fair value, a 21% upside to its current price.

    MKTX Community Fair Values as at Nov 2025

    Five members of the Simply Wall St Community estimate MarketAxess’s fair value between US$140.65 and US$206.63, showing broad differences in opinion. Against this backdrop, fee compression and lost market share remain at the forefront for those considering the company’s next phase.

    Explore 5 other fair value estimates on MarketAxess Holdings – why the stock might be worth 16% less than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include MKTX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Teleflex (TFX) Is Down 12.1% After Goodwill Impairment Drives Steep Net Loss Despite Revenue Growth

    Teleflex (TFX) Is Down 12.1% After Goodwill Impairment Drives Steep Net Loss Despite Revenue Growth

    • Teleflex Incorporated recently reported its third-quarter 2025 financial results, revealing strong revenue growth to US$913.02 million but a significant net loss of US$408.89 million, mainly due to a goodwill impairment charge of US$403.9 million, and announced a new quarterly cash dividend of US$0.34 per share payable in December.

    • An unusual aspect of these results is that, despite outpacing revenue estimates and confirming full-year adjusted earnings targets, Teleflex experienced a severe drop in profitability and narrowed its full-year guidance.

    • We’ll examine how the goodwill impairment and steep operating margin decline impact Teleflex’s investment narrative and future outlook.

    These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.

    Owning Teleflex stock means believing in the company’s ability to overcome recent margin pressures and one-time impairment impacts to resume profitable growth, particularly through innovation and expansion in high-growth procedure markets. The latest goodwill impairment and sharp drop in net profitability do not materially alter the immediate importance of integrating the BIOTRONIK Vascular Intervention business, which remains the primary near-term catalyst, while margin pressures from inflation and weak segments continue as the main risk.

    Among the recent announcements, Teleflex’s substantial non-cash goodwill impairment charge of US$403.9 million stands out as most relevant, as it directly drove the negative net income this quarter and triggered concerns about the value of acquired assets. While this charge is a significant headline figure, it does not change the critical focus on integrating the BIOTRONIK business to capture sustainable revenue growth and enhance margins, a priority that remains essential to the company’s narrative.

    By contrast, investors should be aware that margin pressures from inflation and unfavorable product mix continue to weigh on earnings, raising questions about…

    Read the full narrative on Teleflex (it’s free!)

    Teleflex’s narrative projects $3.9 billion revenue and $553.0 million earnings by 2028. This requires 8.9% yearly revenue growth and a $361.1 million earnings increase from the current $191.9 million.

    Uncover how Teleflex’s forecasts yield a $127.71 fair value, a 17% upside to its current price.

    TFX Community Fair Values as at Nov 2025

    Community members at Simply Wall St have posted five distinct fair value estimates for Teleflex, ranging from US$120 to as high as US$460, highlighting significant divergence in how investors value the company’s long-term potential after recent margin setbacks. With opinion split, considering risks such as ongoing margin compression may be key to understanding performance differences over time.

    Explore 5 other fair value estimates on Teleflex – why the stock might be worth just $120.00!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include TFX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Reassessing Valuation After Analyst Upgrades and New Growth Guidance

    Reassessing Valuation After Analyst Upgrades and New Growth Guidance

    Onto Innovation (ONTO) just released updated guidance for its upcoming quarter, projecting revenue between $250 million and $265 million. This follows a period in which quarterly sales and earnings dipped compared to last year. Industry watchers remain upbeat about the company’s future prospects.

    See our latest analysis for Onto Innovation.

    Onto Innovation’s shares have rebounded sharply in recent weeks, rising over 35% on a 90-day share price return, helped by renewed optimism in memory-related end markets and a technical “Golden Cross” that has caught traders’ attention. However, the stock is still working its way back from a tough year, with a 1-year total shareholder return down nearly 21%. Its impressive 64% three-year and 243% five-year total shareholder returns highlight its long-term growth potential as momentum builds again.

    If Onto’s comeback has you searching for other strong growth stories, now is the perfect time to see what you might uncover with fast growing stocks with high insider ownership.

    With analyst price targets raised and optimism growing around Onto Innovation’s positioning in memory markets, the big question remains: is the recent rally the start of a new uptrend, or is future growth already baked into the price?

    With Onto Innovation closing at $139.09 and the most popular narrative assigning a fair value of $149.38, the stage is set for a debate around what catalysts and growth assumptions support this premium target.

    The accelerating adoption of AI packaging and advanced 2.5D/3D logic architectures is driving a major step up in demand for Onto Innovation’s next-generation Dragonfly systems. Strong customer pull and new applications are expanding both revenue and potential gross margin through higher ASPs and increased market share within leading-edge chip production.

    Read the complete narrative.

    What powers Onto’s premium valuation? The narrative hinges on breakthrough demand from disruptive chip architectures and profit margins that rivals envy. Craving the details behind these projections? Discover which aggressive growth forecasts shape this ambitious fair value.

    Result: Fair Value of $149.38 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, a delay in memory market recovery or unexpected integration challenges with acquisitions could quickly change the outlook and put pressure on Onto’s projected growth story.

    Find out about the key risks to this Onto Innovation narrative.

    While the fair value suggests Onto Innovation is undervalued, taking a look at its earnings multiple reveals a mixed picture. The company trades on a price-to-earnings ratio of 38.9x, which is higher than both the semiconductor industry average of 35.6x and its own fair ratio of 34.8x. This premium could signal investor confidence in future growth or heightened risk if expectations are not met. Does the market know something the models do not?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:ONTO PE Ratio as at Nov 2025

    If the prevailing narrative does not capture your outlook or you want to dig deeper, keep in mind that you can craft your own view quickly and easily. Do it your way.

    A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Onto Innovation.

    Stay ahead by using the Simply Wall Street Screener to hunt for standout opportunities beyond Onto Innovation. Sharpen your strategy with ideas that others might miss.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ONTO.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Aussie Broadband (ASX:ABB) Ticks All The Boxes When It Comes To Earnings Growth

    Aussie Broadband (ASX:ABB) Ticks All The Boxes When It Comes To Earnings Growth

    For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, ‘Long shots almost never pay off.’ Loss making companies can act like a sponge for capital – so investors should be cautious that they’re not throwing good money after bad.

    In contrast to all that, many investors prefer to focus on companies like Aussie Broadband (ASX:ABB), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.

    Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

    Over the last three years, Aussie Broadband has grown earnings per share (EPS) at as impressive rate from a relatively low point, resulting in a three year percentage growth rate that isn’t particularly indicative of expected future performance. So it would be better to isolate the growth rate over the last year for our analysis. Aussie Broadband’s EPS has risen over the last 12 months, growing from AU$0.097 to AU$0.11. That’s a 15% gain; respectable growth in the broader scheme of things.

    It’s often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company’s growth. Aussie Broadband maintained stable EBIT margins over the last year, all while growing revenue 19% to AU$1.2b. That’s a real positive.

    The chart below shows how the company’s bottom and top lines have progressed over time. To see the actual numbers, click on the chart.

    ASX:ABB Earnings and Revenue History November 8th 2025

    View our latest analysis for Aussie Broadband

    The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don’t exist, you can check our visualization of consensus analyst forecasts for Aussie Broadband’s future EPS 100% free.

    It’s pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own Aussie Broadband shares worth a considerable sum. Indeed, they have a considerable amount of wealth invested in it, currently valued at AU$160m. Investors will appreciate management having this amount of skin in the game as it shows their commitment to the company’s future.

    It’s good to see that insiders are invested in the company, but are remuneration levels reasonable? Our quick analysis into CEO remuneration would seem to indicate they are. For companies with market capitalisations between AU$616m and AU$2.5b, like Aussie Broadband, the median CEO pay is around AU$1.5m.

    The Aussie Broadband CEO received AU$1.2m in compensation for the year ending June 2025. That seems pretty reasonable, especially given it’s below the median for similar sized companies. CEO compensation is hardly the most important aspect of a company to consider, but when it’s reasonable, that gives a little more confidence that leadership are looking out for shareholder interests. It can also be a sign of good governance, more generally.

    As previously touched on, Aussie Broadband is a growing business, which is encouraging. Earnings growth might be the main attraction for Aussie Broadband, but the fun does not stop there. Boasting both modest CEO pay and considerable insider ownership, you’d argue this one is worthy of the watchlist, at least. Don’t forget that there may still be risks. For instance, we’ve identified 1 warning sign for Aussie Broadband that you should be aware of.

    While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in AU with promising growth potential and insider confidence.

    Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Continue Reading

  • Independent Non-Executive Chairman of AMA Group Picks Up 2.6% More Stock

    Independent Non-Executive Chairman of AMA Group Picks Up 2.6% More Stock

    Investors who take an interest in AMA Group Limited (ASX:AMA) should definitely note that the Independent Non-Executive Chairman, Brian Austin, recently paid AU$0.99 per share to buy AU$197k worth of the stock. Although the purchase only increased their holding by 2.6%, it is still a solid purchase in our view.

    We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

    In fact, the recent purchase by Independent Non-Executive Chairman Brian Austin was not their only acquisition of AMA Group shares this year. Earlier in the year, they paid AU$1.00 per share in a AU$499k purchase. That means that an insider was happy to buy shares at above the current price of AU$0.93. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

    In the last twelve months AMA Group insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

    View our latest analysis for AMA Group

    ASX:AMA Insider Trading Volume November 8th 2025

    There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

    Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that AMA Group insiders own 8.9% of the company, worth about AU$40m. While this is a strong but not outstanding level of insider ownership, it’s enough to indicate some alignment between management and smaller shareholders.

    It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. However, we note that the company didn’t make a profit over the last twelve months, which makes us cautious. Insiders likely see value in AMA Group shares, given these transactions (along with notable insider ownership of the company). Therefore, you should definitely take a look at this FREE report showing analyst forecasts for AMA Group.

    If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

    For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Continue Reading

  • Assessing Donaldson (DCI) Valuation After Steady Share Price Gains and Strong Long-Term Performance

    Assessing Donaldson (DCI) Valuation After Steady Share Price Gains and Strong Long-Term Performance

    Donaldson Company (DCI) shares have shown steady performance this month, rising as investors continue to consider the company’s latest financial results and broader industry trends. With steady revenue and net income growth, DCI remains a point of conversation.

    See our latest analysis for Donaldson Company.

    Donaldson Company’s share price continues to build positive momentum, climbing more than 4% over the past month and racking up an impressive year-to-date share price return of 29%. While recent gains have attracted attention, the company’s long-term results speak for themselves, with a total shareholder return of 53% over three years and more than 75% over five years. This reflects sustained performance and market confidence.

    If you’re interested in what else is showing strong momentum, this is a great time to broaden your view and discover fast growing stocks with high insider ownership

    But after such strong recent returns, investors may be wondering if Donaldson’s share price is undervalued and offering further upside, or if the market is now fully factoring in the company’s future growth prospects.

    Donaldson Company’s share price closed at $86.86, comfortably above the $80.00 fair value estimated in the most popular narrative. This invites a closer look at what analysts believe is powering the company’s valuation, and why the market may have already priced in much of the anticipated upside.

    Global expansion of environmental regulations and emissions standards is increasing demand for advanced filtration across industrial and transportation sectors. This is positioning Donaldson to achieve record sales in both Industrial Solutions and Mobile Solutions, with a direct positive impact on revenue and earnings growth in FY26 and beyond.

    Read the complete narrative.

    Curious about the projections driving this premium? There is a bold profit margin shift and potential record earnings on the table. Find out the financial levers behind this outlook and the one number that could turn the whole story upside down.

    Result: Fair Value of $80.00 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent delays in bioprocessing and a heavy reliance on aftermarket sales could slow revenue growth or disrupt earnings predictability in the future.

    Find out about the key risks to this Donaldson Company narrative.

    If you see the story differently or want to dig into the details yourself, you can build your own perspective in just a few minutes. Do it your way

    A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding Donaldson Company.

    Get ahead of the market and unlock fresh investment ideas tailored to your strategy by exploring these standout stock selections. Don’t let your next winner slip by.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include DCI.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Valuation Perspectives After Strong Earnings, Raised Guidance, and Strategic Microsoft Partnership

    Valuation Perspectives After Strong Earnings, Raised Guidance, and Strategic Microsoft Partnership

    AvePoint (AVPT) just delivered a notable update for investors, announcing strong quarterly earnings with significant increases in revenue and profit compared to the previous year. The company also raised its full-year guidance, signaling renewed momentum.

    See our latest analysis for AvePoint.

    Despite posting standout earnings and forming a strategic partnership with a key Microsoft channel group, AvePoint’s share price has pulled back recently, dropping over 20% in the past month and sitting down roughly 27% year-to-date. However, its three-year total shareholder return is an impressive 159%, showing long-term holders have been well rewarded even as short-term momentum has faded.

    If AvePoint’s run of news has you thinking bigger, this could be an ideal time to broaden your investing lens and explore fast growing stocks with high insider ownership

    With AvePoint delivering robust growth, boosting guidance, and gaining fresh Wall Street support, investors are left to consider if the recent selloff is an overreaction that offers value or if all future gains are already reflected in the price.

    With AvePoint closing at $12.08 and the most-followed narrative putting fair value over 40% higher, expectations are diverging from the current market pricing. The narrative’s thesis leans heavily on the company’s platform expansion and its evolving industry role.

    The accelerating enterprise adoption of AI tools like Microsoft Copilot, alongside increasing security and data governance challenges, is positioning AvePoint’s data management and governance solutions as mission-critical, which is driving robust customer expansions and higher spending per customer. This acts as a catalyst for sustained revenue growth and stronger net retention rates.

    Read the complete narrative.

    Curious about the bold numerical leaps this narrative is built on? The valuation hinges on a future profit metric more commonly reserved for elite software players and is underpinned by a growth outlook that defies conventional sector averages. Ready to see what is powering this valuation gap? Dive deep to discover which financial projections carry the most weight in the narrative’s fair value.

    Result: Fair Value of $21.02 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, rising competition from cloud giants and AvePoint’s continued reliance on Microsoft’s ecosystem could dampen the outlook and limit future gains.

    Find out about the key risks to this AvePoint narrative.

    Looking from a market multiples angle, AvePoint’s price-to-sales ratio stands at 6.6x, which is notably higher than both the US Software industry average of 4.9x and the peer group average of 4.8x. This premium could signal higher expectations baked into the price, increasing the risk if growth falls short. The fair ratio, calculated at 5.8x, sits below the current mark. Could the market eventually reset closer to this benchmark, or will AvePoint’s momentum justify its elevated valuation?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:AVPT PS Ratio as at Nov 2025

    If you see things differently or want to run the numbers your own way, it only takes a few minutes to craft your own perspective, so why not Do it your way

    A great starting point for your AvePoint research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.

    Smart investors know that real opportunity comes from expanding their watchlist. Unlock fresh insights and jump ahead by scoping out these powerful market themes now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include AVPT.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • RS Group plc (EENEF) Q2 2026 Earnings Call Transcript – Seeking Alpha

    1. RS Group plc (EENEF) Q2 2026 Earnings Call Transcript  Seeking Alpha
    2. RS remains on track despite soft markets  Investors’ Chronicle
    3. RS Group stock rating upgraded to Buy by Deutsche Bank on improved trends  Investing.com
    4. Deutsche Bank backs RS Group for recovery as sales and cash flow steady  Proactive Investors
    5. RS Group posts profit rise amid improved second-quarter sales trend  MarketScreener

    Continue Reading

  • Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs

    Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs

    Pending the results of the ongoing phase 3 SORENTO trial (NCT05050942), increasing the dose or shortening the treatment interval of somatostatin analogs may be a viable route to take for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in need of symptom and/or disease control, according to Jennifer Chan, MD, MPH.

    “We’re awaiting the results of the SORENTO trial, which is looking at a novel highly bioavailable formulation of octreotide, a self-administered formulation of octreotide, that will be addressing this issue of whether dose and bioavailability matter,” Chan said in an interview with OncLive® during the 2025 NANETS Multidisciplinary NET Medical Symposium.1,2

    “In that trial, patients were randomly assigned to receive CAM2029, this novel version of octreotide, or standard dose octreotide or lanreotide. [Results] from that trial [will inform] whether that formulation, which is more bioavailable [than octreotide or lanreotide], may have superior efficacy to standard dosing,” Chan added.

    In the interview, Chan, the clinical director of the Gastrointestinal Cancer Center, director of the Program in Carcinoid and Neuroendocrine Tumors, and an institute physician at Dana-Farber Cancer Institute, and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts, discussed the relationship between dose escalation and symptom control, the evidence that supports potential disease control benefits, and how results from the SORENTO trial could redefine current standards.

    Chan’s Topline Takeaways on Optimizing Somatostatin Analog Use in GEP-NETs

    • Increasing octreotide LAR to 40 mg or 60 mg or shortening lanreotide intervals can improve control of carcinoid syndrome symptoms like flushing and diarrhea.
    • Observational data from trials such as NETTER-1, NETTER-2, and CLARINET FORTE suggest higher doses or shorter dosing intervals may prolong disease stability.
    • The ongoing phase 3 SORENTO trial is testing a novel, self-administered, highly bioavailable octreotide that could reshape somatostatin analog dosing paradigms.

    OncLive: What new data support individualized dose escalation or interval shortening of somatostatin analogs in patients with uncontrolled symptoms or disease progression?

    Chan: We often will adjust the dose of somatostatin analogs either by increasing the dose of octreotide long-acting repeatable [LAR] from the standard dose of 30 mg, [to] 40 mg or 60 mg, if there are uncontrolled symptoms of carcinoid syndrome. Sometimes that dose escalation can help minimize the symptoms of flushing and diarrhea, for instance. We also have information from the control arms from, for instance, the NETTER-1 [NCT01578239] and the NETTER-2 [NCT03972488] trials, that suggest that even in patients who might have higher grade disease, for instance in the NETTER-2 trial, or patients who may have progressed after standard dose somatostatin analog, as was the case in the NETTER-1 trial, that there may be some period of disease control by increasing the dose from 30 mg to 60 mg of octreotide LAR.

    There was also the phase 2 CLARINET FORTE trial [NCT02651987] that showed for lanreotide, another somatostatin analog, that if you shorten the interval from the usual 120 mg every 4 weeks to 120 mg every 2 weeks, patients who had progressed on standard dose [therapy] might achieve some progression-free survival benefit with the dose escalation.

    What factors should guide the decision to intensify or switch somatostatin analog therapy, and how do these strategies align with evolving guideline recommendations?

    In clinical practice, we probably most commonly will escalate the dose. For octreotide, [we’ll either] increase from the standard [dose of] 30 mg to 40 mg or 60 mg to help with symptom control. Uncontrolled carcinoid syndrome is probably the most common reason we adjust the dose.

    The same thing could be said for lanreotide. The 120 mg every 4 weeks, we may give more frequently, either every 3 weeks or every 2 weeks, mainly for symptom control. That is consistent with what’s in the National Comprehensive Cancer Network guidelines, for instance, for dose adjustment for symptom control. There’s less controlled data about dose escalation for disease control, but there are some observational results from the control arms of other studies that suggest [we] may achieve some disease control, but we’re awaiting the results of trials to help us understand that better.

    References

    1. Dose optimisation of SSAs: the evolving story in GEP-NET management; supported by Camurus. Presented at: 2025 NANETS Multidisciplinary NET Medical Symposium; October 23-25, 2025; Austin, Texas.
    2. A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET (SORENTO). Clinicaltrials.gov. Updated November 6, 2025. Accessed November 7, 2025. https://clinicaltrials.gov/study/NCT05050942

    Continue Reading